In Vivo is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction
Brought to you by

Bayer HealthCare to sell Nuvelo's blood clotting agent; ends

Executive Summary

Nuvelo (develops cardiovascular and cancer candidates) licensed Bayer HealthCare exclusive rights to market its Phase III thrombolytic alfimeprase outside of the US. Nuvelo retains exclusive US development and commercialization rights.

Deal Industry
  • Biotechnology
  • Pharmaceuticals
Deal Status
  • Terminated
Deal Type
  • Alliance
    • Includes Contract
    • Includes Royalty or Profit Split Information
    • R&D and Marketing (Licensing)

Related Companies

UsernamePublicRestriction

Register